Opinion
Video
Author(s):
The panel outlines combination therapy options for patients with advanced prostate cancer and discusses the potential benefits of intensification of androgen deprivation therapy.
Radioligand therapy shows promising safety in patients with mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
Dr. Schwen on focal therapies for prostate cancer
Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC
FDA updates in urology: February 2025